HUGE FOURTH OF JULY SALE!! Up to 30% OFF on all products, email or submit a contacts form for pricing or to purchase!

ARA-290

ARA-290 (Cibinetide) – EPO-Derived Peptide

At a Glance: ARA-290, frequently referred to in research as Cibinetide, is a synthetic 11-amino acid peptide specifically engineered from the structure of erythropoietin (EPO). What it is used for: It is utilized in advanced laboratory research to study nerve repair, neuroprotection, and profound anti-inflammatory responses. In lab rat models, researchers study its unique ability to rapidly heal damaged small nerve fibers and alleviate severe neuropathic pain without dangerously increasing red blood cell counts.

Product Overview

ARA-290 represents a major breakthrough in tissue repair and pain management research. While traditional EPO has potent natural healing properties, its long-term use in research is severely limited because it triggers erythropoiesis (the dangerous overproduction of red blood cells and thickening of the blood). ARA-290 was meticulously engineered to completely bypass this pathway. Instead, it selectively targets the body's innate repair mechanisms, making it an incredibly valuable compound for researching the true reversal of small fiber neuropathy, targeted inflammation suppression, and rapid cellular healing in stressed research subjects.

Technical Specifications

  • Molecular Formula: C51H84N16O21

  • Molecular Weight: 1257.32 g/mol

  • CAS Number: 1208243-50-8

    E

  • Sequence Profile: Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (11-amino acid sequence featuring a modified N-terminal pyroglutamate)

Mechanism of Action

ARA-290 initiates profound cellular healing by targeting a highly specific, stress-activated receptor:

Paragon Sports Medicine

  • Innate Repair Receptor (IRR) Agonism: Selectively binds to the IRR, a specialized cellular complex consisting of the EPO receptor (EPOR) and the common beta chain (βc/CD131). The IRR is naturally upregulated by the body only in environments of severe tissue damage or metabolic stress.

  • Non-Erythropoietic Pathway: Unlike natural EPO, ARA-290 cannot bind to the classical EPOR homodimer. This means it exerts zero effect on red blood cell mass, systemic blood pressure, or coagulation pathways, allowing for safe study at high dosages.

  • Inflammatory and Apoptotic Modulation: Upon IRR activation, it instantly dampens pro-inflammatory cytokine cascades (such as TNF-α) and modulates intracellular signaling to prevent apoptosis (programmed cell death) in damaged tissue.

  • Targeted Neuroregeneration: Directly stimulates the repair, elongation, and regrowth of small nerve fibers, offering a mechanical reversal of neuropathic pain pathways rather than merely masking the pain signals centrally.

Primary Research Applications

ARA-290 is a vital compound for in vitro and animal model studies focusing on:

  • Small fiber neuropathy (SFN) and chronic neuropathic pain reversal

  • Type 2 Diabetic neuropathy and high-glucose cellular damage

  • Ischemia-reperfusion injury (specifically kidney, heart, and tissue preservation)

  • Traumatic Brain Injury (TBI), neuroinflammation, and advanced wound healing

Storage & Handling

For optimal stability and structural integrity, store the lyophilized powder at -4°F (-20°C). Once reconstituted, store at 36°F to 46°F (2°C to 8°C), sealed tightly, and strictly protect from moisture and light.

⚠️ Important Disclaimer for Carbon Nova Labs Customers: All information provided is for educational and reference purposes only. ARA-290 is sold strictly for laboratory research use only. This compound is not approved by the FDA for human consumption, therapeutic use, or clinical application.Ensure compliance with all institutional safety protocols and consult qualified professionals before conducting research.